Time for oncologists to opt in for routine opt-out HIV testing?

JAMA

Volumn 304, Issue 3, 2010, Pages 334-339

  Chiao, Elizabeth Y ^a   Dezube, Bruce J ^b   Krown, Susan E ^c   Wachsman, William ^d   Brock, Malcolm V ^e   Giordano, Thomas P ^a   Mitsuyasu, Ronald ^f   Pantanowitz, Liron ^g  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UCSD MEDICAL CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANUS CANCER; BONE CANCER; BRAIN CANCER; CANCER PATIENT; CANCER REGISTRY; CLINICAL PRACTICE; DIAGNOSTIC TEST; EMERGENCY WARD; EYE CANCER; GALLBLADDER CANCER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION RATE; KAPOSI SARCOMA; KIDNEY CANCER; LARYNX CANCER; LEUKEMIA; LIVER CANCER; LUNG CANCER; MULTIPLE MYELOMA; NASOPHARYNX CANCER; NEOPLASM; NONHODGKIN LYMPHOMA; ONCOLOGY; OROPHARYNX CANCER; OVERALL SURVIVAL; PATIENT CARE; PENIS CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SCREENING; SKIN CANCER; SMALL INTESTINE CANCER; STOMACH CANCER; TESTIS CANCER; UNITED STATES; UTERINE CERVIX CANCER; VAGINA CANCER;

EID: 77954733512     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.752     Document Type: Review

References (50)

1. Branson BM, Handsfield HH, Lampe MA, et al; Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1-17.
2. Centers for Disease Control and Prevention. Late HIV testing - 34 states, 1996-2005. MMWR Morb Mortal Wkly Rep. 2009;58(24):661-665.
3. Bartlett JG, Branson BM, Fenton K, Hauschild BC, Miller V, Mayer KH. Opt-out testing for human immunodeficiency virus in the United States: progress and challenges. JAMA. 2008;300(8):945-951.
4. Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Owens DK; Clinical Efficacy Assessment Subcommittee, American College of Physicians. Screening for HIV in health care settings: a guidance statement from the American College of Physicians and HIV Medicine Association. Ann Intern Med. 2009;150(2):125-131.
5. Burke RC, Sepkowitz KA, Bernstein KT, et al. Why don't physicians test for HIV? a review of the US literature. AIDS. 2007;21(12):1617-1624.
6. Sterne JA, May M, Costagliola D, et al; When to Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373(9672):1352- 1363.
7. Kitahata MM, Gange SJ, Abraham AG, et al; NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815-1826.
8. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report: Cases of HIV Infection and AIDS in the United States, 2004. Vol 16. Atlanta, GA: US Dept of Health and Human Services; 2005. http://www.cdc.gov/hiv/stats/ hasrlink.htm. Accessed May 14, 2010.
9. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005;39(4):446-453. (Pubitemid 41003791)
10. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23(11):1397-1404.
11. US Department of Health and Human Services. Medicare expands list of covered preventive services to include HIV screening tests. December 8, 2009. http://www.hhs.gov/news/press/2009pres/12/20091208a.html. Accessed May 9, 2010.
12. Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009;52(5):611-622.
13. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581): 59-67.
14. Chiao EY, Giordano TP, Richardson P, El-Serag HB. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol. 2008;26(3):474-479. (Pubitemid 351171702)
15. Hakimian R, Fang H, Thomas L, Edelman MJ. Lung cancer in HIV-infected patients in the era of highly active antiretroviral therapy. J Thorac Oncol. 2007; 2(4):268-272. (Pubitemid 47181707)
16. Clarke CA, Glaser SL. Population-based surveillance of HIV-associated cancers: utility of cancer registry data. J Acquir Immune Defic Syndr. 2004; 36(5):1083-1091. (Pubitemid 38989375)
17. Cave J, Edwards SG, Miller RF, Ardeshna KM, Lee SM. Should we implement "opt-out" HIV testing for patients with lymphoma? Clin Med. 2009;9(4): 320-322.
18. Cunningham CO, Doran B, DeLuca J, Dyksterhouse R, Asgary R, Sacajiu G. Routine opt-out HIV testing in an urban community health center. AIDS Patient Care STDS. 2009;23(8):619-623.
19. Centers for Disease Control and Prevention. Rapid HIV testing in emergency departments - three US sites, January 2005-March 2006. MMWR Morb Mortal Wkly Rep. 2007;56(24):597-601.
20. Sturtevant D, Preiksaitis J, Singh A, et al. The feasibility of using an "opt-out" approach to achieve universal HIV testing of tuberculosis patients in Alberta. Can J Public Health. 2009;100(2):116-120.
21. Hall HI, Song R, Rhodes P, et al; HIV Incidence Surveillance Group. Estimation of HIV incidence in the United States. JAMA. 2008;300(5):520-529.
22. Owens DK, Sundaram V, Lazzeroni LC, et al. Prevalence of HIV infection among inpatients and outpatients in Department of Veterans Affairs health care systems: implications for screening programs for HIV. Am J Public Health. 2007;97(12):2173-2178.
23. Frisch M, Biggar RJ, Engels EA, Goedert JJ; AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;285(13):1736-1745.
24. Patel P, Hanson DL, Sullivan PS, et al; Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148(10):728-736.
25. Brock MV, Hooker CM, Engels EA, et al. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr. 2006; 43(1):47-55.
26. Kirk GD, Merlo C, O'Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007; 45(1):103-110.
27. Lavolé A, Chouaid C, Baudrin L, et al. Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer. Lung Cancer. 2009;65(3):345-350.
28. Tirelli U, Spina M, Sandri S, et al; Italian Cooperative Group on AIDS and Tumors. Lung carcinoma in 36 patients with human immunodeficiency virus infection. Cancer. 2000;88(3):563-569.
29. Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Curr Opin Oncol. 2009;21(5):445-454.
30. Stadler RF, Gregorcyk SG, Euhus DM, Place RJ, Huber PJ, Simmang CL. Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy. Dis Colon Rectum. 2004;47(8):1305-1309.
31. Berenguer J, Miralles P, Ribera JM, et al. Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47(4):422-428.
32. Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood. 2001;98(8):2339-2344.
33. Knowles DM, Chamulak GA, Subar M, et al. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS): the New York University Medical Center experience with 105 patients (1981-1986). Ann Intern Med. 1988;108(5):744-753.
34. Kaplan LD, Abrams DI, Feigal E, et al. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA. 1989;261(5):719-724.
35. Hoffmann C, Chow KU, Wolf E, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Haematol. 2004; 125(4):455-462.
36. Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D. AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol. 2008;26(29):4834-4842.
37. Powles T, Thirwell C, Newsom-Davis T, et al. Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART? Br J Cancer. 2003;89(3):457-459. (Pubitemid 37026424)
38. Bower M, Powles T, Newsom-Davis T, et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr. 2004; 37(5):1563-1565. (Pubitemid 39658192)
39. Oehler-Jänne C, Huguet F, Provencher S, et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: amulticentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol. 2008;26(15):2550-2557.
40. Abramowitz L, Mathieu N, Roudot-Thoraval F, et al. Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients. Aliment Pharmacol Ther. 2009;30(4):414-421.
41. Hogg ME, Popowich DA, Wang EC, Kiel KD, Stryker SJ, Halverson AL. HIV and anal cancer outcomes: a single institution's experience. Dis Colon Rectum. 2009;52(5):891-897.
42. Bräu N, Fox RK, Xiao P, et al; North American Liver Cancer in HIV Study Group. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a US-Canadian multicenter study. J Hepatol. 2007;47(4):527-537.
43. Mocroft A, Kirk O, Clumeck N, et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. Cancer. 2004; 100(12):2644-2654.
44. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000;92(22):1823-1830.
45. Bower M, Weir J, Francis N, et al. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma. AIDS. 2009;23(13):1701-1706.
46. Levine AM. Management of AIDS-related lymphoma. Curr Opin Oncol. 2008;20(5):522-528.
47. Bower M, Palmieri C, Dhillon T. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis. 2006;19(1):14-19. (Pubitemid 43032434)
48. Seo Y, Kinsella MT, Reynolds HL, Chipman G, Remick SC, Kinsella TJ. Outcomes of chemoradiotherapy with 5-fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys. 2009; 75(1):143-149.
49. Sridhar KS, Flores MR, Raub WA Jr, Saldana M. Lung cancer in patients with human immunodeficiency virus infection compared with historic control subjects. Chest. 1992;102(6):1704-1708. (Pubitemid 23001213)
50. Remick SC. Non-AIDS-defining cancers. Hematol Oncol Clin North Am. 1996;10(5):1203-1213.